Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer: An Open-label, Randomized, Cross-Over Trial.

NCT04409288 is registered in ClinicalTrials.gov with Chinese University of Hong Kong as lead sponsor.

NCT NCT04409288
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04409288 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer: An Open-label, Randomized, Cross-Over Trial.
Lead sponsor
Chinese University of Hong Kong
Phase
Phase 3
Overall status
Terminated
Start date
July 20, 2020
Completion date
October 16, 2023
Enrollment
74 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer